- Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application
- Coeptis Receives Shareholder Approval Towards Z Squared Merger
- Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
- Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating
- Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
- Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared
- Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
- Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement
- COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology
- Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
J.P. Morgan Annual Healthcare Conference
January 8 – January 11, 2024
